Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Ca… Read more
Pulse Biosciences Inc (PLSE) - Net Assets
Latest net assets as of September 2025: $92.69 Million USD
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has net assets worth $92.69 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($108.77 Million) and total liabilities ($16.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $92.69 Million |
| % of Total Assets | 85.22% |
| Annual Growth Rate | 21.73% |
| 5-Year Change | 401.71% |
| 10-Year Change | 740.54% |
| Growth Volatility | 77.23 |
Pulse Biosciences Inc - Net Assets Trend (2014–2024)
This chart illustrates how Pulse Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pulse Biosciences Inc (2014–2024)
The table below shows the annual net assets of Pulse Biosciences Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $114.86 Million | +158.93% |
| 2023-12-31 | $44.36 Million | +2073.31% |
| 2022-12-31 | $-2.25 Million | -106.30% |
| 2021-12-31 | $35.69 Million | +55.89% |
| 2020-12-31 | $22.89 Million | -25.52% |
| 2019-12-31 | $30.74 Million | -53.66% |
| 2018-12-31 | $66.33 Million | +44.22% |
| 2017-12-31 | $45.99 Million | +81.81% |
| 2016-12-31 | $25.30 Million | +85.13% |
| 2015-12-31 | $13.67 Million | -14.99% |
| 2014-12-31 | $16.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pulse Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39022344000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $66.00K | 0.06% |
| Other Components | $505.30 Million | 439.92% |
| Total Equity | $114.86 Million | 100.00% |
Pulse Biosciences Inc Competitors by Market Cap
The table below lists competitors of Pulse Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinosun Tech
SHE:300333
|
$392.33 Million |
|
Guangdong Skychem Technology Co. Ltd. A
SHG:688603
|
$392.62 Million |
|
Universal Stainless & Alloy
NASDAQ:USAP
|
$392.63 Million |
|
Qingdao Kutesmart Co Ltd
SHE:300840
|
$392.90 Million |
|
LINK MOB.GRP.HLDG.NK-005
F:L1N
|
$392.15 Million |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
$392.02 Million |
|
Safari Industries (India) Limited
NSE:SAFARI
|
$391.96 Million |
|
One Liberty Properties Inc
NYSE:OLP
|
$391.80 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulse Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 44,360,000 to 114,862,000, a change of 70,502,000 (158.9%).
- Net loss of 53,585,000 reduced equity.
- Share repurchases of 478,000 reduced equity.
- New share issuances of 59,649,000 increased equity.
- Other factors increased equity by 64,916,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.59 Million | -46.65% |
| Share Repurchases | $478.00K | -0.42% |
| Share Issuances | $59.65 Million | +51.93% |
| Other Changes | $64.92 Million | +56.52% |
| Total Change | $- | 158.93% |
Book Value vs Market Value Analysis
This analysis compares Pulse Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.49x to 11.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $6.40 | $22.32 | x |
| 2015-12-31 | $1.81 | $22.32 | x |
| 2016-12-31 | $2.30 | $22.32 | x |
| 2017-12-31 | $3.12 | $22.32 | x |
| 2018-12-31 | $3.88 | $22.32 | x |
| 2019-12-31 | $1.48 | $22.32 | x |
| 2020-12-31 | $0.98 | $22.32 | x |
| 2021-12-31 | $1.28 | $22.32 | x |
| 2022-12-31 | $-0.07 | $22.32 | x |
| 2023-12-31 | $0.92 | $22.32 | x |
| 2024-12-31 | $1.97 | $22.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulse Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.15x
- Recent ROE (-46.65%) is above the historical average (-78.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -2.95% | 0.00% | 0.00x | 1.11x | $-2.08 Million |
| 2015 | -20.57% | 0.00% | 0.00x | 1.05x | $-4.18 Million |
| 2016 | -37.62% | -13997.06% | 0.00x | 1.04x | $-12.05 Million |
| 2017 | -55.59% | -10351.01% | 0.00x | 1.08x | $-30.17 Million |
| 2018 | -56.60% | 0.00% | 0.00x | 1.06x | $-44.18 Million |
| 2019 | -149.62% | 0.00% | 0.00x | 1.36x | $-49.06 Million |
| 2020 | -217.25% | -43628.95% | 0.00x | 1.80x | $-52.03 Million |
| 2021 | -176.97% | -4454.16% | 0.03x | 1.52x | $-66.73 Million |
| 2022 | 0.00% | -8421.86% | 0.01x | 0.00x | $-58.73 Million |
| 2023 | -95.15% | 0.00% | 0.00x | 1.33x | $-46.65 Million |
| 2024 | -46.65% | 0.00% | 0.00x | 1.15x | $-65.07 Million |
Industry Comparison
This section compares Pulse Biosciences Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulse Biosciences Inc (PLSE) | $92.69 Million | -2.95% | 0.17x | $392.21 Million |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |